Citigroup Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $45

Citigroup maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $66 to $45.

Benzinga · 11/07/2019 12:39

Citigroup maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $66 to $45.